Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1999-02-05
2000-12-26
Weddington, Kevin E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514159, 514822, 424 9464, A61K 3800, A61K 3160, A61K 3848
Patent
active
061659746
ABSTRACT:
There is disclosed a pharmaceutical preparation for treating blood coagulation disorders which comprises purified prothrombinase factors, in particular purified prothrombin and optionally purified factor Xa as active component.
REFERENCES:
patent: 4287180 (1981-09-01), Thomas
patent: 4382083 (1983-05-01), Thomas
patent: 4395396 (1983-07-01), Eibl et al.
patent: 4501731 (1985-02-01), Tishkoff et al.
patent: 4640834 (1987-02-01), Eibl et al.
patent: 4721618 (1988-01-01), Giles et al.
patent: 5120537 (1992-06-01), Esmon et al.
patent: 5585259 (1996-12-01), Lauwereys et al.
patent: 5593968 (1997-01-01), Turecek et al.
patent: 5618788 (1997-04-01), Copon et al.
patent: 5698677 (1997-12-01), Eibl et al.
patent: 5866122 (1999-02-01), Turecek et al.
patent: 5891843 (1999-04-01), Turecek et al.
patent: 6039945 (2000-03-01), Turecek et al.
patent: 6099837 (2000-08-01), Turecek et al.
Vlasuk et al. "Comparison of the In Vitro Anticoagulant Properties of Standard Herparin and the Highly Selective Factor Xa Inhibitors Antistasin and Tick Anticoagulant Peptide (TAP) in a Rabbit Model of Venus Thrombosis", vol. 65, No. 3, 257-262 (1991).
Drouet et al. "The Effect of Recombinant Human Von Willebrand Factor in Pigs with severe Von Willebrand's Disease", Blood, vol. 86, No. 10, 612a-Abs.No. 2435 (1995).
Raymond et al. "Characterization of the Fawn-Hooded Rat as a Model for Hemostatic Studies", Thrombos. Diathes. haemorrh., vol. 33, 361-369 (1975).
"Parenteral Preparations", Remington's Pharmaceutical Sciences, 15th Edition, Easton: Mack Publishing Co., pp. 1461-1487 (1975).
"Isotonic Solutions", Remington's Pharmaceutical Sciences, 15th Edition, Easton: Mack Publishing Co., pp. 1405-1412 (1975).
Wessler et al. "Biologic assay of a thrombosis-inducing activity in human serum", J. Appl. Physiol., vol. 14, No. 6, 943-946 (1959).
Windholz et al. The Merck Index, 10th Ed., Abstract Nos. 3862-3869, pp. 566-567 (1983).
Hedner et al. "Recombinant Activated Factor VII in thr Treatment of Bleeding Episodes in Patients With Inherited and Acquired Bleeding Disorders", Transfusion Medicine Reviews, vol. 7, No. 2, 78-83 (1993).
Tschopp et al. "Hereditary Defect in Platelet Function in Rats", Blood, vol. 40, No. 2, 217-226 (1972).
Giles et al. "A Canine Model of Hemophillic (Factor VIII:C Deficiency) Bleeding", Blood, vol. 60, No. 3, 727-730 (1982).
Brummelius "Preparation of the Prothrombin Complex", Methods of Plasma Protein Fractionation, Curling, J.H. ed., 117-128, Academic Press, New York (1980).
Fareed et al. "Neutralization of Recombinant Hirudin: Some Practical Considerations", Seminars in Thrombosis and Homeostasis, vol. 17, No. 2, 137-144 (1991).
Fareed et al. "Some Objective Consideration for the Neutralization of the Anticoagulant Actions of Recombinant Hirudin", Haemostasis, vol. 21, (suppl. 1), 64-72 (1991).
Irani et al. "Reversal of Hirudin-Induced Bleeding Diathesis by Prothrombin Complex Concentrate", The American Journal of Cardiology, vol. 75, 422-423 (1995).
Pryzdial et al. J. Biol. Chem. 270(30): 17871-17877 (1995) (Abstract).
Eibl Johann
Schwarz Hans-Peter
Turecek Peter
Baxter Aktiengesellschaft
Weddington Kevin E.
LandOfFree
Pharmaceutical preparation for treating blood coagulation disord does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical preparation for treating blood coagulation disord, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical preparation for treating blood coagulation disord will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-994859